NEW YORK (GenomeWeb News) — Ciphergen’s sale of its proteomics tools business to Bio-Rad did not close on Nov. 1 as originally expected.
 
After Ciphergen’s shareholders approved the sale last week the company said it expected the transaction to close before Nov. 1. But as of yesterday the deal had not closed.
 
A Bio-Rad spokeswoman declined to comment on the delay but said Wednesday that the deal could be finished within the next few days.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.